Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification

被引：24
|
作者：
Palma, Norma [1 ]
Morris, John C. [2 ]
Ali, Siraj M. [1 ]
Ross, Jeffrey S. [1 ,3 ]
Pal, Sumanta Kumar [4 ]
机构：
[1] Fdn Med, Cambridge, MA USA
[2] Univ Cincinnati, Inst Canc, Div Hematol Oncol, Cincinnati, OH USA
[3] Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA
[4] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA
来源：
EUROPEAN UROLOGY | 2015年 / 68卷 / 01期
关键词：
D O I：
10.1016/j.eururo.2015.02.023
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：168 / 170
页数：4
相关论文
共 50 条
  • [31] Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine
    van Rhijn, BWG
    Lurkin, I
    Chopin, DK
    Kirkels, WJ
    Thiery, JP
    van der Kwast, TH
    Radvanyi, F
    Zwarthoff, EC
    CLINICAL CANCER RESEARCH, 2003, 9 (01) : 257 - 263
  • [32] Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
    Nagata, Yujiro
    Minato, Akinori
    Aono, Hisami
    Kimuro, Rieko
    Higashijima, Katsuyoshi
    Tomisaki, Ikko
    Harada, Kenichi
    Miyamoto, Hiroshi
    Fujimoto, Naohiro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (19)
  • [33] Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?
    Mota, Jose Mauricio S. C.
    Teo, Min Yuen
    Li, Han
    Balar, Arjun Vasant
    Milowsky, Matthew I.
    Funt, Samuel Aaron
    Lee, Chung-Han
    Regazzi, Ashley Marie
    Berger, Michael F.
    Solit, David B.
    Bajorin, Dean F.
    Rosenberg, Jonathan E.
    Iyer, Gopa
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma
    Limaye, Sewanti
    Patil, Darshana
    Akolkar, Dadasaheb
    Srivastava, Navin
    Patil, Revati
    Apurwa, Sachin
    Patil, Sanket
    John, Jinumary
    Gosavi, Rahul
    Nesargikar, Prabhu
    Kumar, Prashant
    Datta, Vineet
    Bose, Chirantan
    Raazi, Zarrine
    Srinivasan, Ajay
    Datar, Rajan
    CLINICAL CASE REPORTS, 2021, 9 (11):
  • [35] Mutations of TERT promoter and FGFR3 in urothelial carcinoma of urinary bladder in Korean patients
    Choi, C.
    Kim, S-S.
    Byeun, J-Y.
    VIRCHOWS ARCHIV, 2017, 471 : S279 - S279
  • [36] Fibroblast Growth Factor Receptor 3 Epidermal Naevus Syndrome with Urothelial Mosaicism for the Activating p.Ser249Cys FGFR3 Mutation
    Bessis, Didier
    Plaisancie, Julie
    Gaston, Veronique
    Bieth, Eric
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (03) : 402 - 403
  • [37] Activating Fgfr3 Mutation In Immature Osteoblasts Affects Appendicular And Cranio-facial Skeleton
    Duplan, Martin Biosse
    Dambroise, Emilie
    Estibals, Valentin
    Veziers, Joelle
    Guicheux, Jerome
    Legeai-Mallet, Laurence
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 44 - 44
  • [38] Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
    Young Saing Kim
    Kyung Kim
    Ghee-Young Kwon
    Su Jin Lee
    Se Hoon Park
    BMC Urology, 18
  • [39] FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
    Adel H Jebar
    Carolyn D Hurst
    Darren C Tomlinson
    Colin Johnston
    Claire F Taylor
    Margaret A Knowles
    Oncogene, 2005, 24 : 5218 - 5225
  • [40] Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
    Kim, Young Saing
    Lee, Soon Il
    Park, Se Hoon
    CANCER RESEARCH, 2018, 78 (13)
12345